Spots Global Cancer Trial Database for diffuse intrinsic pontine glioma
Every month we try and update this database with for diffuse intrinsic pontine glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | NCT01182350 | Diffuse Intrins... | Bevacizumab Erlotinib Temozolomide Radiation | 3 Years - 18 Years | Dana-Farber Cancer Institute | |
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | NCT03355794 | Diffuse Intrins... Malignant Gliom... High Grade Glio... Bithalamic High... Brainstem Gliom... Glioblastoma Anaplastic Astr... | ribociclib Everolimus | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository | NCT03101813 | Diffuse Intrins... Diffuse Midline... Diffuse Midline... | - | Children's Hospital Medical Center, Cincinnati | ||
| Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | NCT01400672 | Diffuse Intrins... | Tumor Lysate Va... Imiquimod Radiation thera... | 3 Years - | Masonic Cancer Center, University of Minnesota | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT04978727 | Medulloblastoma Glioblastoma Mu... Anaplastic Astr... High-grade Astr... Anaplastic Olig... Anaplastic Epen... Ependymoma Diffuse Intrins... | SurVaxM for pat... SurVaxM for pat... SurVaxM for pat... | 1 Year - 21 Years | Pediatric Brain Tumor Consortium | |
| Targeted Pediatric High-Grade Glioma Therapy | NCT05839379 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | 12 Months - 39 Years | Nationwide Children's Hospital | ||
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | NCT03330197 | Pediatric Brain... Diffuse Intrins... | Ad-RTS-hIL-12 Oral Veledimex ... Oral Veledimex ... | 0 Years - 21 Years | Alaunos Therapeutics | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| xPedite: A Study to Expedite DIPG and DMG Research | NCT06140719 | Oncology DIPG DMG | - | xCures | ||
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | NCT03033992 | Malignant Gliom... Ependymoma Diffuse Intrins... | Optune System (... Concurrent Optu... | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma | NCT04911621 | High Grade Glio... Diffuse Intrins... | Dendritic cell ... Dendritic cell ... | 12 Months - 17 Years | University Hospital, Antwerp | |
| Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | NCT05518838 | Diffuse Midline... Diffuse Intrins... | OKN-007 | 13 Months - 18 Years | Oblato, Inc. | |
| Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma | NCT00600054 | Recurrent Diffu... | nimotuzumab (an... | 3 Years - 18 Years | YM BioSciences | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | NCT04943848 | Diffuse Intrins... Diffuse Midline... | rHSC-DIPGVax Balstilimab Zalifrelimab | 12 Months - 18 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | NCT04264143 | Diffuse Intrins... Diffuse Pontine... Diffuse Midline... | Infusate with M... Convection-Enha... | 3 Years - 18 Years | Columbia University | |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | NCT04655404 | High Grade Glio... Diffuse Intrins... | Larotrectinib Larotrectinib s... | - 21 Years | Nationwide Children's Hospital | |
| Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | NCT01400672 | Diffuse Intrins... | Tumor Lysate Va... Imiquimod Radiation thera... | 3 Years - | Masonic Cancer Center, University of Minnesota | |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | NCT05009992 | Diffuse Intrins... Diffuse Midline... Recurrent Diffu... Recurrent Diffu... Recurrent WHO G... WHO Grade III G... | ONC201 Radiation Thera... Paxalisib | 2 Years - 39 Years | University of California, San Francisco | |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | NCT01837862 | Pilomyxoid Astr... Pilocytic Astro... Glioma, Astrocy... Optic Nerve Gli... Pleomorphic Xan... Glioblastoma Mu... Anaplastic Astr... Gliosarcoma Diffuse Intrins... DIPG Low-grade Gliom... Brainstem Gliom... | Mebendazole Vincristine Carboplatin Temozolomide Bevacizumab Irinotecan | 1 Year - 21 Years | Northwell Health | |
| Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) | NCT01644773 | Diffuse Intrins... High-grade Glio... | Crizotinib Dasatinib | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents | NCT01517776 | Gliomas | Cilengitide Temozolomide | 3 Years - 17 Years | Martin-Luther-Universität Halle-Wittenberg | |
| PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma | NCT01393912 | Diffuse Intrins... Progressive or ... | Crenolanib | 18 Months - 21 Years | St. Jude Children's Research Hospital | |
| Study of Ribociclib and Everolimus in HGG and DIPG | NCT05843253 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | Ribociclib Everolimus | 12 Months - 39 Years | Nationwide Children's Hospital | |
| ONC201 in Pediatric H3 K27M Gliomas | NCT03416530 | Diffuse Intrins... Glioma, Maligna... | ONC201 | 2 Years - 18 Years | Chimerix | |
| Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma | NCT04749641 | Diffuse Intrins... | Histone H3.3-K2... | 5 Years - | Beijing Tiantan Hospital | |
| Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | NCT03033992 | Malignant Gliom... Ependymoma Diffuse Intrins... | Optune System (... Concurrent Optu... | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | NCT01445288 | Diffuse Intrins... PNET Ependymoma Germinoma Medulloblastoma | 1 Month - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | NCT04051047 | Glial Tumor of ... Diffuse Intrins... Glioma | Gemcitabine Tumor biopsy an... | 3 Years - 17 Years | University of Michigan Rogel Cancer Center | |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | NCT06333899 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Infant Type Hem... Glioblastoma Glioblastoma Mu... WHO Grade III G... WHO Grade IV Gl... Diffuse Midline... | Lorlatinib Lorlatinib with... Lorlatinib with... Lorlatinib post... | 1 Year - 21 Years | Nationwide Children's Hospital | |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | NCT04655404 | High Grade Glio... Diffuse Intrins... | Larotrectinib Larotrectinib s... | - 21 Years | Nationwide Children's Hospital | |
| MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma | NCT03566199 | Diffuse Intrins... | Panobinostat Na... Convection-Enha... | 2 Years - 21 Years | University of California, San Francisco | |
| Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717699 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) | NCT01469247 | Brain Cancer | Radiation Thera... | - 17 Years | M.D. Anderson Cancer Center | |
| Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | NCT02644460 | Diffuse Intrins... Brain Tumor, Re... Solid Tumor, Re... Neuroblastoma, ... Ewing Sarcoma, ... Rhabdomyosarcom... Osteosarcoma, R... Rhabdoid Tumor,... | Abemaciclib | 2 Years - 25 Years | Emory University | |
| International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) | NCT03243461 | Glioblastoma WH... Diffuse Midline... Anaplastic Astr... Diffuse Intrins... Gliomatosis Cer... | Temozolomide + ... | 3 Years - 17 Years | University of Göttingen | |
| Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT01189266 | Anaplastic Astr... Anaplastic Olig... Diffuse Intrins... Gliosarcoma | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Vorinostat | 37 Months - 21 Years | National Cancer Institute (NCI) | |
| Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | NCT00879437 | Glial Cell Tumo... Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Gliomatosis Cer... Gliosarcoma Brainstem Gliom... Diffuse Intrins... | Valproic acid Bevacizumab Radiation thera... | 3 Years - 21 Years | Baylor College of Medicine | |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG | NCT04341311 | Diffuse Intrins... Pediatric Brain... Pediatric Brain... Pediatric Cance... Pediatric Brain... Diffuse Glioma | Marizomib Panobinostat | - 21 Years | Dana-Farber Cancer Institute | |
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | NCT05768880 | Diffuse Intrins... Diffuse Midline... Recurrent CNS T... Recurrent, CNS ... Refractory Prim... | SC-CAR4BRAIN | 1 Year - 26 Years | Seattle Children's Hospital | |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | NCT04655404 | High Grade Glio... Diffuse Intrins... | Larotrectinib Larotrectinib s... | - 21 Years | Nationwide Children's Hospital | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | NCT05476939 | Diffuse Intrins... Diffuse Midline... | Everolimus ONC201 Radiotherapy | 6 Months - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | NCT01922076 | Anaplastic Astr... Anaplastic Olig... Diffuse Intrins... Diffuse Midline... Glioblastoma Gliosarcoma | Adavosertib Laboratory Biom... Pharmacological... Radiation Thera... | 37 Months - 21 Years | National Cancer Institute (NCI) | |
| Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma | NCT04749641 | Diffuse Intrins... | Histone H3.3-K2... | 5 Years - | Beijing Tiantan Hospital | |
| Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma | NCT02992015 | Diffuse Intrins... | Gemcitabine | 3 Years - 17 Years | University of Colorado, Denver | |
| Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | NCT02420613 | Diffuse Intrins... | Radiation Thera... Temsirolimus Vorinostat | 7 Months - 21 Years | M.D. Anderson Cancer Center | |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | NCT05099003 | Anaplastic Astr... Anaplastic Astr... Diffuse Intrins... Diffuse Midline... Glioblastoma Glioblastoma, N... Malignant Gliom... | Biopsy Magnetic Resona... Radiation Thera... Selinexor | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | NCT01106794 | Diffuse Intrins... Brainstem Gliom... | - 21 Years | Children's National Research Institute | ||
| Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717699 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy | NCT04837547 | Neuroblastoma Diffuse Intrins... | Tumor-specific ... | 1 Year - 30 Years | University of Florida | |
| A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) | NCT04771897 | Diffuse Intrins... Diffuse Midline... | BXQ-350 - Part ... BXQ-350 - Part ... | 1 Year - 30 Years | Bexion Pharmaceuticals, Inc. | |
| A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | NCT02607124 | High Grade Glio... Diffuse Intrins... Bithalamic High... | Ribociclib | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | NCT02960230 | Diffuse Intrins... Glioma Diffuse Midline... | K27M peptide Nivolumab | 3 Years - 21 Years | University of California, San Francisco | |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | NCT02758366 | Glioblastoma (G... DIPG Brainstem Gliom... Diffuse Spinal ... Bilateral Thala... Gliomatosis Cer... Anaplastic Astr... Midline Diffuse... | Doxorubicin | 3 Years - 30 Years | Meyer Children's Hospital IRCCS | |
| Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | NCT05717712 | Oncolytic Virus Diffuse Intrins... Adverse Drug Ev... | Ad-TD-nsIL12 | 1 Year - 18 Years | Capital Medical University | |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | NCT03330197 | Pediatric Brain... Diffuse Intrins... | Ad-RTS-hIL-12 Oral Veledimex ... Oral Veledimex ... | 0 Years - 21 Years | Alaunos Therapeutics | |
| Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | NCT02420613 | Diffuse Intrins... | Radiation Thera... Temsirolimus Vorinostat | 7 Months - 21 Years | M.D. Anderson Cancer Center | |
| International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository | NCT03101813 | Diffuse Intrins... Diffuse Midline... Diffuse Midline... | - | Children's Hospital Medical Center, Cincinnati | ||
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | NCT05956821 | Glioblastoma Mu... Anaplastic Astr... Fibrillary Astr... Oligodendroglio... Diffuse Intrins... Diffuse Intrins... DIPG Brain Tumo... H3 K27M | SIACI of cetuxi... | 1 Year - 21 Years | University of Miami | |
| Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | NCT05518838 | Diffuse Midline... Diffuse Intrins... | OKN-007 | 13 Months - 18 Years | Oblato, Inc. | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | NCT02233049 | Diffuse Intrins... | Erlotinib Everolimus Dasatinib | 6 Months - 25 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | NCT05768880 | Diffuse Intrins... Diffuse Midline... Recurrent CNS T... Recurrent, CNS ... Refractory Prim... | SC-CAR4BRAIN | 1 Year - 26 Years | Seattle Children's Hospital | |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NCT02502708 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... Ependymoma Medulloblastoma Diffuse Intrins... Primary CNS Tum... | Indoximod Temozolomide Conformal Radia... Cyclophosphamid... Etoposide | 3 Years - 21 Years | Lumos Pharma | |
| Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses | NCT03620032 | Diffuse Intrins... | Nimotuzumab Vinorelbine Radiotherapy | 2 Years - 21 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma | NCT04911621 | High Grade Glio... Diffuse Intrins... | Dendritic cell ... Dendritic cell ... | 12 Months - 17 Years | University Hospital, Antwerp | |
| RE-irradiation of Diffuse MIdline Glioma paTients | NCT06093165 | Diffuse Midline... Diffuse Intrins... Diffuse Glioma Pontine Tumors Thalamic Tumor Brain Tumor, Pe... | Re-irradiation | 12 Months - 21 Years | Rigshospitalet, Denmark | |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | NCT05956821 | Glioblastoma Mu... Anaplastic Astr... Fibrillary Astr... Oligodendroglio... Diffuse Intrins... Diffuse Intrins... DIPG Brain Tumo... H3 K27M | SIACI of cetuxi... | 1 Year - 21 Years | University of Miami | |
| Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines | NCT02840123 | Diffuse Intrins... | Autologous dend... | 3 Years - 18 Years | Fundació Sant Joan de Déu | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | NCT02233049 | Diffuse Intrins... | Erlotinib Everolimus Dasatinib | 6 Months - 25 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | NCT05476939 | Diffuse Intrins... Diffuse Midline... | Everolimus ONC201 Radiotherapy | 6 Months - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | NCT05099003 | Anaplastic Astr... Anaplastic Astr... Diffuse Intrins... Diffuse Midline... Glioblastoma Glioblastoma, N... Malignant Gliom... | Biopsy Magnetic Resona... Radiation Thera... Selinexor | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG | NCT06221553 | DIPG Brain Tumo... Diffuse Intrins... | B7H3 specific C... | 1 Year - 18 Years | Chulalongkorn University | |
| H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | NCT02960230 | Diffuse Intrins... Glioma Diffuse Midline... | K27M peptide Nivolumab | 3 Years - 21 Years | University of California, San Francisco | |
| A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | NCT03632317 | Glioma Diffuse Intrins... | Panobinostat Everolimus | 2 Years - 30 Years | University of Michigan Rogel Cancer Center | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
